# A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

Study · id `cardio:ct-nct04017832` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04017832](<https://clinicaltrials.gov/study/NCT04017832>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04017832

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1441 participants.

## Technical summary

Registry record NCT04017832. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-29 (actual); primary completion 2021-10-27 (actual). Results posted on 2023-09-29.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1441 participants (enrolled count; ClinicalTrials.gov record NCT04017832, source copy `cardio:ctgov-nct04017832-2024-10-01`, retrieved 2026-10-26)
- Started: 2019-07-29 (actual) (ClinicalTrials.gov record NCT04017832, source copy `cardio:ctgov-nct04017832-2024-10-01`, retrieved 2026-10-26)
- Primary completion: 2021-10-27 (actual) (ClinicalTrials.gov record NCT04017832, source copy `cardio:ctgov-nct04017832-2024-10-01`, retrieved 2026-10-26)
- Completion: 2021-10-27 (actual) (ClinicalTrials.gov record NCT04017832, source copy `cardio:ctgov-nct04017832-2024-10-01`, retrieved 2026-10-26)
- Results first posted: 2023-09-29 (ClinicalTrials.gov record NCT04017832, source copy `cardio:ctgov-nct04017832-2024-10-01`, retrieved 2026-10-26)
- Countries: Algeria; Brazil; China; Czechia; Hong Kong SAR China; Romania; Serbia; South Africa; Taiwan (ClinicalTrials.gov record NCT04017832, source copy `cardio:ctgov-nct04017832-2024-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04017832-2024-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
- Acronym: PIONEER 12
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Oral semaglutide
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Placebo (oral semaglutide)
- Intervention (Drug): Placebo (sitagliptin)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial (`cardio:pubmed-38985161`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f7b33b715aac77d43ccbcef81d626e42c0ef42a4d4d2c6c35547ae1f828a4df5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
